Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01196975 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Adults
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,707
- Enrollment target
NCT01196975: Completed Phase 3 study, sponsored by GlaxoSmithKline.
NCT01196975 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 1,707 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (121% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01196975, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,707 participants
- Enrollment target
Study Summary
This study is designed to test the immunogenicity and safety of an investigational influenza vaccine, in adults compared to two other influenza vaccines. This study will also evaluate the lot-to-lot consistency of three vaccine lots.
Primary Outcome
Titers are presented as geometric mean titers (GMTs). The reference cut-off value was 1:10. Antibodies assessed were antibodies against the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (BRI) and FLU B/Florida/4/06 (FLO) flu strains. Results for Day 21 for the subjects in the GSK2282512A Group are the results specific to this primary outcome measure.
Interventions
- BIOLOGICAL Quadrivalent seasonal influenza vaccine GSK2282512A
- BIOLOGICAL FluLavalTM-VB
- BIOLOGICAL FluLavalTM-YB
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,707 participants |
| Start Date | 2010-10-01 |
| Est. Completion | 2011-06-24 |
| Phase | Phase 3 |
What the finished NCT01196975 record still lists
NCT01196975 is an interventional study that assigns participants to a tested intervention. Its 1,707 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (121% higher).
The record links to 0 conditions, and to 3 interventions - of which Quadrivalent seasonal influenza vaccine GSK2282512A is the first listed.
NCT01196975 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01196975 about?
NCT01196975 is a clinical study titled "A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Adults". This study is designed to test the immunogenicity and safety of an investigational influenza vaccine, in adults compared to two other influenza vaccines. This study will also evaluate the lot-to-lot consistency of three vaccine lots.
What is the current status of trial NCT01196975?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,707 participants. The study started on 2010-10-01. Estimated completion is 2011-06-24.
What interventions are being tested in trial NCT01196975?
The interventions under investigation include: Quadrivalent seasonal influenza vaccine GSK2282512A (BIOLOGICAL), FluLavalTM-VB (BIOLOGICAL), FluLavalTM-YB (BIOLOGICAL).
Who is sponsoring clinical trial NCT01196975?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01196975's enrollment target sits among peer trials
1,707 132nd of 2000 higher than 1,869 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07304531 · 1,705 participants
First To Know Pregnancy Test - Clinical Evaluation Protocol
- NCT05303636 · 1,710 participants · Phase 4
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women
- NCT04321200 · 1,700 participants
PANDA Gym: Automated Assessment of Neurodevelopment in Infants at Risk for Motor Disability
- NCT06238622 · 1,700 participants · Phase 3
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI